Could it be beneficial to harness a potentially devastating virus, such as Zika virus, for use in medical treatment? At first glance, this seems somewhat counterintuitive. Yet a news release…
Could something that you're exposed to while still in the womb impact your health? Although it may not be something we think about often, the answer is yes. What we're…
According to Yahoo Finance, immuno-oncology company Surface Oncology ("Surface") recently received Orphan Drug designation for its leading therapeutic candidate SRF617. Altogether, this therapy is designed to treat patients with pancreatic…
Recently, the National Cancer Institute provided a $2.5M grant to support specialized medical research being performed at the Wake Forest Organoid Research Center (WFORCE). According to the press release,…
In a press release from early March 2021, radiopharmaceutical therapy company Molecular Targeting Technologies, Inc. ("MTTI") shared that the FDA approved its Investigational New Drug (IND) application for EBTATE.…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Genomic testing is a great way to learn not just about your genes, but how your genes impact your health. In support of the Phase 2 CRESTONE clinical trial, a…
The drug development process is not always easy or quick. It consists of drug discovery, preclinical and clinical research, and FDA approval. However, sometimes developers are sent back to the…
First formed and launched within the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI), biopharmaceutical company Linnaeus Therapeutics, Inc. ("Linnaeus") is now making strides in the…
Molecular Targeting Technologies (MTTI), a radiopharmaceutical company, announced through Biospace that the FDA has given its approval for MTTI to move forward with a Phase 1 clinical trial to study…
On March 11, 2021, global biopharmaceutical company Alkermes plc shared that its investigational drug candidate nemvaleukin alfa received Orphan Drug designation from the FDA. The treatment is designed for patients…
Biopharmaceutical company OncoSynergy recently shared that the first patient was dosed in a Phase 1 clinical trial. Within this trial, researchers are exploring OS2966 for patients with recurrent glioblastoma.…
According to a recent article featured in News5Cleveland.com, there are over seven thousand rare diseases worldwide that affect over thirty million people in the United States. Several days ago, patients…
Some cancers and hematological conditions can be difficult to treat. But biotechnology company Oncopeptides AB is working to address this issue for patients with relapsed or refractory (R/R) multiple…
The FDA's Orphan Drug designation offers a special status to drugs or biologics designed to treat rare conditions. In the United States, a rare disease is one that impacts less…
In a recent press release, biopharmaceutical company Salarius Pharmaceuticals, Inc. ("Salarius") shared that it had initiated an expansion stage of a Phase 1/2 clinical trial. Within the trial and the…
In a joint statement, biopharmaceutical companies AstraZeneca and Merck & Co., Inc. ("Merck") shared that LYNPARZA (olaparib) achieved a superiority boundary in the Phase 3 OlympiA clinical trial. During…
There is a new collaboration in the rare cancer space which could lead to improved therapies for individuals living with these conditions. Sheperd Therapeutics and Oncoheroes Biosciences have announced that…
In some cases, elderly patients (those over 70 years old) with esophageal cancer have been told that surgery is not the best option. This stems from a belief that…
The NCCN, or National Comprehensive Cancer Network, has recently published treatment guidelines for children living with a rare kidney cancer, Wilms tumor. This is the organization's first guidelines written for…
According to Targeted Oncology, the first patient was dosed in a Phase 1 clinical trial evaluating NBTXR3, an investigational tumor-agnostic radio enhancer, for patients with esophageal cancer. The trial will…
Typically, the pathway to diagnosis for endometrial cancer can be long, uncomfortable, and invasive: transvaginal ultrasounds, biopsies. However, this may be about to change. In a recent press release, Arquer…
In a recent press release, pharmaceutical company Moleculin Biotech, Inc. ("Moleculin") shared a recent advance in the sphere of medical and health research. Agencja Badań Medycznych, a Polish agency which contributes…
According to Oncology Nursing News, a new study performed by researchers at the Baylor College of Medicine used germline testing to identify genetic precursors to pediatric rhabdomyosarcoma. The study identified…
Zymeworks Inc. has recently began enrollment for an expansion cohort of the Phase 1 trial of ZW49. ZW49 is an antibody-drug conjugate (ADC) that targets HER2 positive cancer cells. This…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
